Enliven Therapeutics (ELVN) Net Income towards Common Stockholders (2019 - 2026)

Enliven Therapeutics has disclosed Net Income towards Common Stockholders across 8 years of filings, most recently posting -$23.6 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$23.6 million, up 17.09% year-over-year; the trailing twelve-month figure through Mar 2026 was -$891000.0 (up 99.07% YoY), and the FY2025 annual result was -$5.8 million, up 93.59% from the prior year.
• Net Income towards Common Stockholders came in at -$23.6 million for Q1 2026 at Enliven Therapeutics, down from $68.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $68.2 million in Q4 2025 to a low of -$28.5 million in Q1 2025.
• The 5-year median for Net Income towards Common Stockholders is -$20.1 million (2025), against an average of -$13.4 million.
• Across the five-year window, Net Income towards Common Stockholders sank 102.73% in 2023 and jumped 394.29% in 2025, its largest moves.
• Enliven Therapeutics' Net Income towards Common Stockholders stood at -$9.5 million in 2022, then tumbled by 102.73% to -$19.4 million in 2023, then decreased by 19.73% to -$23.2 million in 2024, then surged by 394.29% to $68.2 million in 2025, then slumped by 134.64% to -$23.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$23.6 million (Q1 2026), $68.2 million (Q4 2025), and -$20.1 million (Q3 2025), per Business Quant data.